Chemotherapy for Well-Differentiated Pancreatic Neuroendocrine Tumours with a Ki-67 Index ≥10%: Is There a More Effective Antitumour Regimen? A Retrospective Multicentre Study of the French Group of Endocrine Tumours (GTE) | Zendy

Guillaume Roquin | Zendy; Eric Baudin | Zendy; Catherine LombardBohas | Zendy; Guillaume Cadiot | Zendy; Sophie Dominguez | Zendy; Rosine Guimbaud | Zendy; Patricia Niccoli | Zendy; Jean-Louis Legoux | Zendy; Emmanuel Mitry | Zendy; V. Rohmer | Zendy; Philippe Ruszniewski | Zendy; Thomas Walter | Zendy; Michel Ducreux | Zendy; Anne Couvelard | Zendy; Jean–Yves Scoazec | Zendy; Aline RamondRoquin | Zendy; FrançoisXavier CaroliBosc | Zendy; Olivia Hentic | Zendy

Open Access

Chemotherapy for Well-Differentiated Pancreatic Neuroendocrine Tumours with a Ki-67 Index ≥10%: Is There a More Effective Antitumour Regimen? A Retrospective Multicentre Study of the French Group of Endocrine Tumours (GTE)

Author(s) -

Guillaume Roquin,

Eric Baudin,

Catherine LombardBohas,

Guillaume Cadiot,

Sophie Dominguez,

Rosine Guimbaud,

Patricia Niccoli,

Jean-Louis Legoux,

Emmanuel Mitry,

V. Rohmer,

Philippe Ruszniewski,

Thomas Walter,

Michel Ducreux,

Anne Couvelard,

Jean–Yves Scoazec,

Aline RamondRoquin,

FrançoisXavier CaroliBosc,

Olivia Hentic

Publication year - 2017

Publication title -

neuroendocrinology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.493

H-Index - 101

eISSN - 1423-0194

pISSN - 0028-3835

DOI - 10.1159/000457955

Subject(s) - medicine , dacarbazine , temozolomide , chemotherapy , regimen , chemotherapy regimen , neuroendocrine tumors , progression free survival , oncology , gastroenterology , surgery

The best chemotherapy regimen for well- differentiated pancreatic neuroendocrine tumours (pNETs) with a Ki-67 index ≥10% is still debated. We evaluated the antitumour efficacy of various first-line chemotherapy regimens (streptozocin based, platinum based, or dacarbazine/temozolomide based) in this situation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research